(ALC) Alcon - Overview

Sector: HealthcareIndustry: Medical Instruments & Supplies | Exchange NYSE (USA) | Currency USD | Market Cap: 37.222m | Total Return -22.1% in 12m

Stock Surgical Equipment, Lenses, Contact Lenses, Eye Care
Total Rating 36
Risk 77
Buy Signal -1.20
Medical Instruments & Supplies -3.5
Health Care Equipment -3.1
Market Cap: 37,222m
Avg Trading Vol: 115M USD
ATR: 2.51%
Peers RS (IBD): 42.9
Risk 5d forecast
Volatility25.2%
Rel. Tail Risk-7.84%
Reward TTM
Sharpe Ratio-0.94
Alpha-32.72
Character TTM
Beta0.572
Beta Downside0.192
Drawdowns 3y
Max DD28.24%
CAGR/Max DD0.08
EPS (Earnings per Share) EPS (Earnings per Share) of ALC over the last years for every Quarter: "2021-03": 0.49, "2021-06": 0.56, "2021-09": 0.54, "2021-12": 0.56, "2022-03": 0.68, "2022-06": 0.63, "2022-09": 0.5, "2022-12": 0.42, "2023-03": 0.7, "2023-06": 0.69, "2023-09": 0.66, "2023-12": 0.69, "2024-03": 0.78, "2024-06": 0.74, "2024-09": 0.81, "2024-12": 0.57, "2025-03": 0.73, "2025-06": 0.76, "2025-09": 0.79, "2025-12": 0.78, "2026-03": 0,
EPS CAGR: -45.98%
EPS Trend: -7.0%
Last SUE: -4.00
Qual. Beats: 0
Revenue Revenue of ALC over the last years for every Quarter: 2021-03: 1930, 2021-06: 2110, 2021-09: 2102, 2021-12: 2149, 2022-03: 2189, 2022-06: 2217, 2022-09: 2140, 2022-12: 2171, 2023-03: 2352, 2023-06: 2422, 2023-09: 2329, 2023-12: 2352, 2024-03: 2459, 2024-06: 2496, 2024-09: 2454, 2024-12: 2502, 2025-03: 2473, 2025-06: 2596, 2025-09: 2614, 2025-12: 2718, 2026-03: null,
Rev. CAGR: 5.94%
Rev. Trend: 94.1%
Last SUE: 0.94
Qual. Beats: 1
Description: ALC Alcon March 05, 2026

Alcon Inc. develops, manufactures, and sells eye care products globally through two segments: Surgical and Vision Care. The companys business model focuses on both surgical solutions and routine vision needs.

The Surgical segment provides equipment, instruments, diagnostics, and consumables for ophthalmic procedures. This includes intraocular lenses (IOLs), which are a key component of cataract surgery, a common procedure in the aging global population. Products range from cataract and vitreoretinal systems to refractive surgery tools.

The Vision Care segment offers daily disposable, reusable, and color-enhancing contact lenses, alongside ocular health products for conditions like dry eye and glaucoma. The global contact lens market is characterized by ongoing innovation in materials and designs for comfort and vision correction.

For more detailed financial analysis, consider exploring ValueRay.

Headlines to Watch Out For
  • Aging global population increases demand for surgical and vision care products
  • New product launches in IOLs and contact lenses drive revenue growth
  • Increased competition in contact lens market impacts pricing and market share
  • Regulatory approvals for new ophthalmic devices influence market entry and sales
Piotroski VR‑10 (Strict, 0-10) 6.0
Net Income: 980.0m TTM > 0 and > 6% of Revenue
FCF/TA: 0.05 > 0.02 and ΔFCF/TA 0.36 > 1.0
NWC/Revenue: 32.69% < 20% (prev 40.67%; Δ -7.98% < -1%)
CFO/TA 0.07 > 3% & CFO 2.25b > Net Income 980.0m
Net Debt (3.72b) to EBITDA (1.90b): 1.96 < 3
Current Ratio: 2.12 > 1.5 & < 3
Outstanding Shares: last quarter (492.3m) vs 12m ago -1.05% < -2%
Gross Margin: 54.82% > 18% (prev 0.56%; Δ 5.43k% > 0.5%)
Asset Turnover: 33.60% > 50% (prev 32.66%; Δ 0.95% > 0%)
Interest Coverage Ratio: 2.92 > 6 (EBITDA TTM 1.90b / Interest Expense TTM 204.8m)
Altman Z''
A: 0.11 (Total Current Assets 6.45b - Total Current Liabilities 3.05b) / Total Assets 31.55b
B: error (Retained Earnings missing)
C: 0.02 (EBIT TTM 598.0m / Avg Total Assets 30.95b)
D: 2.31 (Book Value of Equity 22.03b / Total Liabilities 9.52b)
Beneish M -3.11
DSRI: 0.89 (Receivables 1.94b/2.08b, Revenue 10.40b/9.91b)
GMI: 1.01 (GM 54.82% / 55.61%)
AQI: 1.00 (AQ_t 0.63 / AQ_t-1 0.63)
SGI: 1.05 (Revenue 10.40b / 9.91b)
TATA: -0.04 (NI 980.0m - CFO 2.25b) / TA 31.55b)
Beneish M-Score: -3.11 (Cap -4..+1) = AA
What is the price of ALC shares? As of March 31, 2026, the stock is trading at USD 73.67 with a total of 1,276,571 shares traded.
Over the past week, the price has changed by -0.63%, over one month by -15.50%, over three months by -7.11% and over the past year by -22.12%.
Is ALC a buy, sell or hold? Alcon has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy ALC.
  • StrongBuy: 15
  • Buy: 6
  • Hold: 6
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the ALC price?
ISSUER TARGET UP/DOWN
Wallstreet Target Price 95.3 29.4%
Analysts Target Price 95.3 29.4%
ALC Fundamental Data Overview March 28, 2026
P/E Trailing = 37.6111
P/E Forward = 21.7391
P/S = 3.5787
P/B = 1.6489
P/EG = 1.6985
Revenue TTM = 10.40b USD
EBIT TTM = 598.0m USD
EBITDA TTM = 1.90b USD
Long Term Debt = 509.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 655.0m USD (from shortTermDebt, last quarter)
Debt = 5.25b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.72b USD (from netDebt column, last quarter)
Enterprise Value = 40.86b USD (37.22b + Debt 5.25b - CCE 1.61b)
Interest Coverage Ratio = 2.92 (Ebit TTM 598.0m / Interest Expense TTM 204.8m)
EV/FCF = 23.91x (Enterprise Value 40.86b / FCF TTM 1.71b)
FCF Yield = 4.18% (FCF TTM 1.71b / Enterprise Value 40.86b)
FCF Margin = 16.43% (FCF TTM 1.71b / Revenue TTM 10.40b)
Net Margin = 9.42% (Net Income TTM 980.0m / Revenue TTM 10.40b)
Gross Margin = 54.82% ((Revenue TTM 10.40b - Cost of Revenue TTM 4.70b) / Revenue TTM)
Gross Margin QoQ = 54.19% (prev 55.78%)
Tobins Q-Ratio = 1.29 (Enterprise Value 40.86b / Total Assets 31.55b)
Interest Expense / Debt = 1.01% (Interest Expense 53.0m / Debt 5.25b)
Taxrate = 17.80% (47.0m / 264.0m)
NOPAT = 491.5m (EBIT 598.0m * (1 - 17.80%))
Current Ratio = 2.12 (Total Current Assets 6.45b / Total Current Liabilities 3.05b)
Debt / Equity = 0.24 (Debt 5.25b / totalStockholderEquity, last quarter 22.03b)
Debt / EBITDA = 1.96 (Net Debt 3.72b / EBITDA 1.90b)
Debt / FCF = 2.18 (Net Debt 3.72b / FCF TTM 1.71b)
Total Stockholder Equity = 22.05b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.17% (Net Income 980.0m / Total Assets 31.55b)
RoE = 4.44% (Net Income TTM 980.0m / Total Stockholder Equity 22.05b)
RoCE = 2.65% (EBIT 598.0m / Capital Employed (Equity 22.05b + L.T.Debt 509.0m))
RoIC = 1.84% (NOPAT 491.5m / Invested Capital 26.77b)
WACC = 7.11% (E(37.22b)/V(42.47b) * Re(8.0%) + D(5.25b)/V(42.47b) * Rd(1.01%) * (1-Tc(0.18)))
Discount Rate = 8.0% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.09%
[DCF] Terminal Value 84.54% ; FCFF base≈1.64b ; Y1≈2.02b ; Y5≈3.45b
[DCF] Fair Price = 141.0 (EV 72.44b - Net Debt 3.72b = Equity 68.72b / Shares 487.4m; r=7.11% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -6.98 | EPS CAGR: -45.98% | SUE: -4.0 | # QB: 0
Revenue Correlation: 94.05 | Revenue CAGR: 5.94% | SUE: 0.94 | # QB: 1
EPS next Quarter (2026-06-30): EPS=0.49 | Chg7d=+0.000 | Chg30d=+0.367 | Revisions Net=-2 | Analysts=6
EPS current Year (2026-12-31): EPS=3.44 | Chg7d=+0.003 | Chg30d=+0.027 | Revisions Net=+9 | Growth EPS=+12.1% | Growth Revenue=+7.1%
EPS next Year (2027-12-31): EPS=2.80 | Chg7d=-0.001 | Chg30d=-0.061 | Revisions Net=-2 | Growth EPS=+20.5% | Growth Revenue=+6.4%
[Analyst] Revisions Ratio: -1.00 (0 Up / 2 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.3% (Discount Rate 8.0% - Earnings Yield 2.7%)
[Growth] Growth Spread = +1.9% (Analyst 7.3% - Implied 5.3%)
Additional Sources for ALC Stock Fund Manager Positions: Dataroma · Stockcircle